ATE450187T1 - Verhinderung von hautlappennekrose in der plastischen chirurgie - Google Patents

Verhinderung von hautlappennekrose in der plastischen chirurgie

Info

Publication number
ATE450187T1
ATE450187T1 AT02804687T AT02804687T ATE450187T1 AT E450187 T1 ATE450187 T1 AT E450187T1 AT 02804687 T AT02804687 T AT 02804687T AT 02804687 T AT02804687 T AT 02804687T AT E450187 T1 ATE450187 T1 AT E450187T1
Authority
AT
Austria
Prior art keywords
necrosis
flape
prevention
skin
plastic surgery
Prior art date
Application number
AT02804687T
Other languages
English (en)
Inventor
Jonathan Stamler
Michael Zenn
Eric Toone
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE450187T1 publication Critical patent/ATE450187T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AT02804687T 2001-12-06 2002-12-02 Verhinderung von hautlappennekrose in der plastischen chirurgie ATE450187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33617501P 2001-12-06 2001-12-06
PCT/US2002/036138 WO2003049593A2 (en) 2001-12-06 2002-12-02 Prevention of flap necrosis in plastic surgery

Publications (1)

Publication Number Publication Date
ATE450187T1 true ATE450187T1 (de) 2009-12-15

Family

ID=23314894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804687T ATE450187T1 (de) 2001-12-06 2002-12-02 Verhinderung von hautlappennekrose in der plastischen chirurgie

Country Status (8)

Country Link
US (1) US20060153931A1 (de)
EP (1) EP1463440B1 (de)
JP (2) JP4563679B2 (de)
AT (1) ATE450187T1 (de)
AU (1) AU2002365036B2 (de)
CA (1) CA2467245A1 (de)
DE (1) DE60234642D1 (de)
WO (1) WO2003049593A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
AU2005235309B2 (en) 2004-04-19 2012-07-26 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
EP2445492B1 (de) 2009-06-24 2016-09-28 Strategic Science & Technologies, LLC Topische zusammensetzung mit ibuprofen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2658551B1 (de) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Behandlung von erektionsstörungen und anderen indikationen
CN105878172A (zh) 2010-12-29 2016-08-24 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
WO2020185674A1 (en) * 2019-03-08 2020-09-17 South Dakota Board Of Regents A vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing
CN112843241B (zh) * 2021-01-14 2023-07-25 中国药科大学 可生物响应的一氧化氮供体型聚合物前药及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
JP2599031B2 (ja) * 1990-11-30 1997-04-09 宇部興産株式会社 高純度亜硝酸アルキルエステルの製造法
DK0719145T3 (da) * 1994-05-27 2001-01-02 Cellegy Pharma Inc Nitrogenoxiddonorpræparat til behandling af anale lidelser
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
CA2299049C (en) * 1997-05-02 2008-07-15 Baxter Biotech Technology S.A.R.L. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
HUP0104676A3 (en) * 1998-12-14 2005-12-28 Cellegy Pharmaceuticals Inc So Compositions for the treatment of anorectal disorders and their use
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6359182B1 (en) * 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof

Also Published As

Publication number Publication date
EP1463440A2 (de) 2004-10-06
CA2467245A1 (en) 2003-06-19
WO2003049593A3 (en) 2004-02-19
DE60234642D1 (de) 2010-01-14
JP2010047619A (ja) 2010-03-04
US20060153931A1 (en) 2006-07-13
EP1463440A4 (de) 2008-01-23
JP4563679B2 (ja) 2010-10-13
JP5266191B2 (ja) 2013-08-21
JP2005511708A (ja) 2005-04-28
AU2002365036B2 (en) 2006-09-21
AU2002365036A1 (en) 2003-06-23
WO2003049593A2 (en) 2003-06-19
EP1463440B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
MX2010004549A (es) Composiciones y métodos bacteriostáticos o bactericidas.
ATE450187T1 (de) Verhinderung von hautlappennekrose in der plastischen chirurgie
ECSP099427A (es) Barra de Tierra Segunda Generación 16 conexiones
BR0312023A (pt) Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
DE50310516D1 (de) Fredericamycin-derivate
CY1113286T1 (el) Συνθεση με στροντιο και βιταμινη d για την προφυλαξη ή/καιθεραπευτικη αντιμετωπιση των παθησεων των χονδρων ή/και των οστων
ATE505488T1 (de) Modulator von coagulationskaskaden und fibrinolytischen kaskaden
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
CY1109513T1 (el) Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
BRPI0515582A (pt) 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
EE200300476A (et) 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
ATE341343T1 (de) Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
SE0102147D0 (sv) New methods
EA200500941A1 (ru) Средство для лечения болезней суставов
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties